Breztri Aerosphere is a triple-therapy inhaler that combines three active medications, each targeting a different aspect of COPD. It works by reducing airway inflammation while simultaneously opening the airways through two distinct relaxation pathways. The result is broader coverage than any single medication or dual combination can achieve on its own.
Three Medications, Three Jobs
Each puff of Breztri delivers three drugs that attack breathing problems from different angles:
- Budesonide is a corticosteroid that reduces inflammation inside the airways. Swollen, inflamed airways are a hallmark of COPD, and budesonide calms that swelling within hours of inhalation. Over time, this lowers the frequency of flare-ups (exacerbations).
- Glycopyrrolate is a long-acting bronchodilator that works by blocking a specific receptor on the smooth muscle lining the airways. When this receptor is blocked, the muscles relax and the airways widen. It’s particularly effective in the larger, central airways of the lungs.
- Formoterol is also a long-acting bronchodilator, but it works through a completely different chemical pathway. It activates a signaling process inside airway muscle cells that causes them to relax. Formoterol is especially effective in the smaller, peripheral airways deeper in the lungs.
Because glycopyrrolate and formoterol relax airways through different mechanisms and in different parts of the lung, combining them produces broader bronchodilation than either one alone. Layering budesonide on top addresses the underlying inflammation that triggers many COPD symptoms and exacerbations in the first place.
How Quickly It Starts Working
Breztri has a notably fast onset. In clinical trials, most patients experienced a measurable improvement in lung function, at least 100 mL of additional air volume, within 5 minutes of the first dose. That rapid response comes primarily from formoterol and glycopyrrolate, both of which begin relaxing airway muscles almost immediately after inhalation.
The anti-inflammatory effects of budesonide take longer to build. You may notice fewer flare-ups and gradually easier breathing over weeks of consistent use, even though the bronchodilator effect is nearly instant.
How the Inhaler Delivers All Three Drugs
Getting three medications into the same inhaler and ensuring they all reach the right parts of your lungs is an engineering challenge. Breztri uses a system called co-suspension technology: all three drugs are attached to tiny, low-density porous particles made of phospholipid, a naturally occurring fat. These carrier particles keep the medication evenly mixed in the canister so each puff delivers a consistent dose. They’re also aerodynamically efficient, meaning they travel deep into both the large and small airways rather than just coating the back of your throat.
Because all three active ingredients ride on the same carrier particles, they deposit together on the airway surface. This co-deposition means the anti-inflammatory and the two bronchodilators arrive at the same locations in your lungs at the same time.
Standard Dosing
The standard dose is 2 puffs twice a day, once in the morning and once in the evening. Each actuation delivers a fixed combination of all three medications. You should not exceed 2 inhalations per session, and Breztri is not designed as a rescue inhaler for sudden breathing emergencies. It’s a maintenance treatment meant to be used on a regular daily schedule.
How Well It Reduces Flare-Ups
The ETHOS trial, one of the largest studies of Breztri, followed patients for a full year. Those on triple therapy experienced roughly 1.25 moderate-to-severe exacerbations per year, compared to 1.63 per year for patients taking only the two bronchodilators without the corticosteroid, and 1.47 per year for those on a corticosteroid plus a single bronchodilator. That translates to about one fewer flare-up for every three to four patients treated with Breztri over a year, a meaningful difference for people whose exacerbations lead to emergency visits or hospitalizations.
Improvements in baseline lung function were more modest. In the 24-week KRONOS trial, the difference in resting lung capacity between Breztri and the dual bronchodilator combination was small and not statistically significant. The primary benefit of adding the corticosteroid component is exacerbation prevention rather than a dramatic boost in everyday airflow.
Who It’s Designed For
Breztri is FDA-approved for maintenance treatment of COPD. Current international guidelines recommend triple therapy for patients who continue to have exacerbations despite already using two medications, particularly when blood eosinophil counts (a marker of a certain type of inflammation) are at or above 300 cells per microliter. In practical terms, if you’ve been on a dual inhaler and still having flare-ups, triple therapy like Breztri is the typical next step.
Breztri has also been studied in asthma, and the most common side effects reported in asthma trials were upper respiratory infections, pneumonia, and headache. However, its primary established role remains in COPD management.
Common Side Effects
The most frequently reported side effects in COPD trials (occurring in 2% or more of patients) include upper respiratory tract infections, pneumonia, back pain, oral thrush (a yeast infection in the mouth), flu, muscle spasms, urinary tract infections, cough, sinus infections, and diarrhea. Oral thrush is a known risk with any inhaled corticosteroid. Rinsing your mouth with water after each use and spitting it out helps reduce that risk.
Pneumonia rates in the year-long ETHOS trial were 4.2% for Breztri, compared to 2.3% for the dual bronchodilator group. This small increase in pneumonia risk is a well-documented trade-off with inhaled corticosteroids in COPD and is one reason doctors reserve triple therapy for patients who genuinely need it rather than prescribing it as a first-line treatment.